Industry estimates suggest more than 50 generic variants both oral and injectable could soon flood the market
The class includes semaglutide (Wegovy, Ozempic, Rybelsus), tirzepatide (Zepbound, Mounjaro, a dual GLP-1/GIP receptor agonist), liraglutide (Saxenda, Victoza), dulaglutide (Trulicity), exenatide (Byetta, Bydureon), and lixisenatide (Adlyxin)
My coach is excellent
Full-Scale Clinical Platform: $250,000 $500,000+ A comprehensive ecosystem with automated Prior Authorizations, deep EHR integrations, AI-driven side-effect triage, and real-time data syncing from wearables
Fugh-Berman is particularly concerned about the marketing of these drugs to children
doi:10.1111/cen.14056 22